Evidence map›Paper›PMID 25664322›Full record

ReviewBioMed research international2015

Antibacterial mechanisms of polymyxin and bacterial resistance.

Zhiliang Yu, Wangrong Qin, Jianxun Lin, Shisong Fang, Juanping Qiu

Registry-linked trialAbstract readReview
In one paragraph

Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06834971 (Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia), which is not on this map. Cited by 127 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06834971 narecruitingnot on this mapstarted 2025, after this paper: background citation

Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial

TypeinterventionalSponsorQilu Hospital of Shandong UniversityRan2025 to 2026Enrolled508ConditionsVentilator-Associated Pneumonia (VAP)ArmsColistimethate sodium (CMS)
3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Lipopolysaccharide-targeting treatments for multidrug-resistantExpert opinion on therapeutic targets · 2026
    Review
  5. Appraisal of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  6. Article
  7. α-Terpineol reversesFrontiers in cellular and infection microbiology · 2026
    Article
  8. Colistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhiliang YuCollege of Biological and Environmental Engineering, Zhejiang University of Technology, Hangzhou 310014, China.ORCID 0000-0003-4849-7055
Wangrong QinCollege of Biological and Environmental Engineering, Zhejiang University of Technology, Hangzhou 310014, China.
Jianxun LinDepartment of Electrical Engineering, Columbia University, New York City, NY 10027, USA.ORCID 0000-0001-6874-8128
Shisong FangShenzhen Center for Disease Control and Prevention, Shenzhen 518055, China.
Juanping QiuCollege of Biological and Environmental Engineering, Zhejiang University of Technology, Hangzhou 310014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance in pathogens is an increasingly significant threat for human health. Indeed, some strains are resistant to almost all currently available antibiotics, leaving very limited choices for antimicrobial clinical therapy. In many such cases, polymyxins are the last option available, although their use increases the risk of developing resistant strains. This review mainly aims to discuss advances in unraveling the mechanisms of antibacterial activity of polymyxins and bacterial tolerance together with the description of polymyxin structure, synthesis, and structural modification. These are expected to help researchers not only develop a series of new polymyxin derivatives necessary for future medical care, but also optimize the clinical use of polymyxins with minimal resistance development.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialHumansPolymyxinsSignal TransductionSpecies SpecificityAnti-Bacterial AgentsPolymyxins

Identifiers

PMID25664322
PMCPMC4312571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.